Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition

Rani Therapeutics Holdings

15/05/2026 21:14

Overview

US biotherapeutics firm's Q1 contract revenue rose, driven by Chugai collaboration

Q1 net loss narrowed yr/yr as operating expenses declined

Company announced CFO transition and new leadership appointments

Outlook

Company expects cash reserves to fund operations into the fourth quarter of 2027

Result Drivers

CHUGAI COLLABORATION - Increase in contract revenue was primarily due to the collaboration and license agreement with Chugai

LOWER COMPENSATION COSTS - Decline in research and development and general and administrative expenses was mainly due to lower compensation costs

Company press release: ID:nGNX8mYKvp

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.04
Q1 Net Income
-$8.02 mln
Q1 Operating Expenses
$10.05 mln
Q1 Operating Income
-$8.34 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Rani Therapeutics Holdings Inc is $7.00, about 530.6% above its May 14 closing price of $1.11

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)